한글목차

약제 요약

Viridian의 주요 제품 후보물질인 VRDN-001은 인슐린 유사 성장인자 1 수용체(IGF-1R)를 표적으로 하는 분화 단클론 항체로서, 임상 및 상업적 검증을 거쳐 베체트병 안질환 치료제로 개발되고 있습니다.

전 임상시험에서 VRDN-001은 IGF-1R의 완전한 길항제로서 유일하게 승인된 다른 항 IGF-1R 항체를 포함한 다른 항-IGF-1R 항체보다 더 완벽하게 수용체를 차단하는 것으로 나타났습니다. 현재 진행 중인 임상 2상 시험의 첫 번째 투여 코호트에서 얻은 데이터는 활동성 그레이브스병 안질환 환자에서 VRDN-001의 임상적 개념 증명을 확립했습니다. 현재 진행 중인 임상시험의 예비 데이터에 따르면 VRDN-001은 임상적으로 유의미한 전안부 증상 감소, 임상적 활동성 점수(CAS) 개선, 복시 소실 등의 효과를 보였으며, VRDN-001은 임상시험에서 전반적으로 안전하고 내약성이 양호한 것으로 나타났습니다.

주요 7 시장(미국·독일·프랑스·이탈리아·스페인·영국·일본)의 그레이브스 안병증용 VRDN-001에 대해 조사분석했으며, 작용기서, 용법과 용량, 연구개발 활동에 관한 인사이트, 매출의 예측 등을 제공하고 있습니다.

목차

제1장 리포트의 서론

제2장 그레이브스 안병증에서의 VRDN-001 개요

• 제품의 상세
• 임상 개발
  • 임상 연구
  • 임상시험 정보
  • 안전성과 유효성
• 기타 개발 활동
• 제품 개요

제3장 경쟁 구도(출시 치료법)

제4장 경쟁 구도(후기 신치료법)

제5장 VRDN-001 시장 평가

• 그레이브스 안병증에서 VRDN-001의 시장 전망
• 주요 7 시장 분석
  • 주요 7 시장 그레이브스 안병증용 VRDN-001의 시장 규모
• 시장 분석 : 국가별
  • 미국의 그레이브스 안병증용 VRDN-001의 시장 규모
  • 독일의 그레이브스 안병증용 VRDN-001의 시장 규모
  • 영국의 그레이브스 안병증용 VRDN-001의 시장 규모

제6장 SWOT 분석

제7장 애널리스트의 견해

제8장 부록

제9장 DelveInsight의 서비스 내용

제10장 면책사항

제11장 DelveInsight 소개

제12장 리포트 구입 옵션

영문목차

"VRDN-001 Market Size, Forecast, and Emerging Insight - 2032" report provides comprehensive insights about VRDN-001 for Graves' Ophthalmopathy in the seven major markets. A detailed picture of the VRDN-001 for Graves' Ophthalmopathy in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the VRDN-001 for Graves' Ophthalmopathy. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the VRDN-001 market forecast analysis for Graves' Ophthalmopathy in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in Graves' Ophthalmopathy.

Drug Summary:

Viridian's lead product candidate, VRDN-001, is a differentiated monoclonal antibody targeting insulin-like growth factor-1 receptor (IGF-1R), a clinically and commercially validated target for the treatment of Graves' Ophthalmopathy.

In preclinical studies, VRDN-001 had shown to be a full antagonist of IGF-1R, with complete receptor blockade than other anti-IGF-1R antibodies, including the only approved Graves' Ophthalmopathy therapy. Data from the initial dose cohorts of the Phase II portion of the ongoing trial established clinical proof-of-concept for VRDN-001 in patients with active Graves' Ophthalmopathy. Preliminary data from the ongoing trial showed treatment with VRDN-001 led to clinically meaningful reductions in proptosis, improvement in clinical activity score (CAS), and diplopia resolution. VRDN-001 was generally safe and well-tolerated in the trial.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the VRDN-001 description, mechanism of action, dosage and administration, research and development activities in Graves' Ophthalmopathy.
• Elaborated details on VRDN-001 regulatory milestones and other development activities have been provided in this report.
• The report also highlights the VRDN-001 research and development activities in Graves' Ophthalmopathy across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around VRDN-001.
• The report contains forecasted sales of VRDN-001 for Graves' Ophthalmopathy till 2032.
• Comprehensive coverage of the late-stage emerging therapies for Graves' Ophthalmopathy.
• The report also features the SWOT analysis with analyst views for VRDN-001 in Graves' Ophthalmopathy.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

VRDN-001 Analytical Perspective by DelveInsight

• In-depth VRDN-001 Market Assessment

This report provides a detailed market assessment of VRDN-001 for Graves' Ophthalmopathy in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2025 to 2032.

• VRDN-001 Clinical Assessment

The report provides the clinical trials information of VRDN-001 for Graves' Ophthalmopathy covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for Graves' Ophthalmopathy is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence VRDN-001 dominance.
• Other emerging products for Graves' Ophthalmopathy are expected to give tough market competition to VRDN-001 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of VRDN-001 in Graves' Ophthalmopathy.
• Our in-depth analysis of the forecasted sales data of VRDN-001 from 2025 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the VRDN-001 in Graves' Ophthalmopathy.

Key Questions:

• What is the product type, route of administration and mechanism of action of VRDN-001?
• What is the clinical trial status of the study related to VRDN-001 in Graves' Ophthalmopathy and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the VRDN-001 development?
• What are the key designations that have been granted to VRDN-001 for Graves' Ophthalmopathy?
• What is the forecasted market scenario of VRDN-001 for Graves' Ophthalmopathy?
• What are the forecasted sales of VRDN-001 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how are these giving competition to VRDN-001 for Graves' Ophthalmopathy?
• Which are the late-stage emerging therapies under development for the treatment of Graves' Ophthalmopathy?

Table of Contents

1. Report Introduction

2. VRDN-001 Overview in Graves' Ophthalmopathy

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Other Developmental Activities
• 2.4. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. VRDN-001 Market Assessment

• 5.1. Market Outlook of VRDN-001 in Graves' Ophthalmopathy
• 5.2. 7MM Analysis
  • 5.2.1. Market Size of VRDN-001 in the 7MM for Graves' Ophthalmopathy
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of VRDN-001 in the United States for Graves' Ophthalmopathy
  • 5.3.2. Market Size of VRDN-001 in Germany for Graves' Ophthalmopathy
  • 5.3.3. Market Size of VRDN-001 in France for Graves' Ophthalmopathy
  • 5.3.4. Market Size of VRDN-001 in Italy for Graves' Ophthalmopathy
  • 5.3.5. Market Size of VRDN-001 in Spain for Graves' Ophthalmopathy
  • 5.3.6. Market Size of VRDN-001 in the United Kingdom for Graves' Ophthalmopathy
  • 5.3.7. Market Size of VRDN-001 in Japan for Graves' Ophthalmopathy

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options